PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.9300
-0.1400 (-2.76%)
At close: 4:00PM EDT

4.9300 0.00 (0.00%)
After hours: 4:07PM EDT

Stock chart is not supported by your current browser
Previous Close5.0700
Open5.1200
Bid4.9000 x 4000
Ask5.0000 x 2900
Day's Range4.9200 - 5.1200
52 Week Range3.6200 - 9.4200
Volume832,523
Avg. Volume1,267,088
Market Cap416.794M
Beta (3Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com12 days ago

    Investor Altiva Wants to Repopulate Progenics’ Board

    In a series of filings concerning the Pennsylvania-based bank over the past week, activists CT Opportunity Management and Driver Management disclosed that they had submitted proposed terms on March 23. The activist investors, filing together on April 4, reported that DNB Financial had declined to accept the term sheet.

  • How Many Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.13 days ago

    How Many Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of PGNX earnings conference call or presentation 14-Mar-19 12:30pm GMT

    Q4 2018 Progenics Pharmaceuticals Inc Earnings Call

  • Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates
    Zackslast month

    Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates

    Progenics (PGNX) delivered earnings and revenue surprises of -112.50% and -70.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Simply Wall St.4 months ago

    What Did Progenics Pharmaceuticals, Inc.’s (NASDAQ:PGNX) CEO Take Home Last Year?

    In 2011 Mark Baker was appointed CEO of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...

  • Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates
    Zacks5 months ago

    Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates

    Progenics (PGNX) delivered earnings and revenue surprises of 50.00% and 28.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Generic-Drugs Stock Outlook: No Respite from Pricing Issues
    Zacks7 months ago

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

  • Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
    Market Realist7 months ago

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).

  • Simply Wall St.7 months ago

    Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 32.98% Discount

    I am going to run you through how I calculated the intrinsic value of Progenics Pharmaceuticals Inc (NASDAQ:PGNX) by estimating the company’s future cash flows and discounting them to their Read More...

  • Progenics Pharma's Stock Down on Dismal Phase III Study Data
    Zacks7 months ago

    Progenics Pharma's Stock Down on Dismal Phase III Study Data

    Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.

  • Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today
    Motley Fool7 months ago

    Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today

    A phase 3 trial failed, but all isn't lost for the biotech.

  • CNBC7 months ago

    After-hours buzz: PVTL, PGNX & more

    Check out the companies making headlines after the bell: Pivotal Software PVTL shares tumbled more than 20 percent in after-hours trading despite reporting second-quarter earnings numbers that beat on both the top and bottom line.

  • Amicus Therapeutics: Recent Developments, Financial Overview
    Market Realist7 months ago

    Amicus Therapeutics: Recent Developments, Financial Overview

    In August, the FDA approved Amicus Therapeutics’ (FOLD) Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease along with an amenable galactosidase alpha gene variant. The FDA’s approval of Galafold was according to the accelerated approval process based on the decrease in KIC GL-3 (kidney interstitial capillary cell globotriaosylceramide) substrate. Studies estimate that more than 3,000 individuals in the United States have Fabry disease.

  • How Analysts View Amicus Therapeutics in September
    Market Realist7 months ago

    How Analysts View Amicus Therapeutics in September

    On September 10, Amicus Therapeutics (FOLD) announced the regulatory and clinical progress of its AT-GAA development program for Pompe disease. The company has met with the FDA to discuss the regulatory trajectory for AT-GAA, and the FDA has provided final written minutes of the meeting. Amicus Therapeutics has implemented the suggestions of the FDA and the European Medicines Agency for the study.

  • Analysts Are Bullish on Verastem in September
    Market Realist7 months ago

    Analysts Are Bullish on Verastem in September

    On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

  • Why Invitae Stock Rose 23% in Week Ended August 24
    Market Realist8 months ago

    Why Invitae Stock Rose 23% in Week Ended August 24

    On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99. It hit its 52-week high of $12.75 on August 24. For the week ended August 24, Invitae stock closed at $12.56, which represents a ~23% rise from its prior week’s close of $10.21 on August 17. Invitae delivered solid growth in the second quarter of 2018 when it reported revenues of $37.3 million compared to $14.3 million in Q2 2017.

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist8 months ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realist8 months ago

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • Opko Health: Q2 Expenditures, Developments, Recommendations
    Market Realist8 months ago

    Opko Health: Q2 Expenditures, Developments, Recommendations

    In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.

  • How Opko Health Fared in the Second Quarter of 2018
    Market Realist8 months ago

    How Opko Health Fared in the Second Quarter of 2018

    In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.

  • 3 Stocks That Could Double Your Money
    Motley Fool9 months ago

    3 Stocks That Could Double Your Money

    Find out why these three biotech stocks could be huge winners.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool10 months ago

    3 Biotech Stocks With Major Catalysts Incoming

    The third quarter of 2018 will be awfully exciting for owners of these three stocks.

  • 4 Drug and Biotech Stocks Awaiting FDA Decisions in July
    Zacks10 months ago

    4 Drug and Biotech Stocks Awaiting FDA Decisions in July

    In the first six months of the year, the FDA grants approval to 17 new treatments.

  • 3 Biotech Stocks With Major Potential Catalysts in July
    Motley Fool10 months ago

    3 Biotech Stocks With Major Potential Catalysts in July

    FDA approvals next month could be huge for these biotech stocks.